Format

Send to

Choose Destination
Rheumatology (Oxford). 2015 Sep;54(9):1699-708. doi: 10.1093/rheumatology/kev114. Epub 2015 May 8.

Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.

Author information

1
Service de Rhumatologie, CHU de la Cavale Blanche, EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, Brest.
2
Service de Rhumatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Le Kremlin Bicêtre.
3
Service de Rhumatologie, Hôtel-Dieu, CHU Nantes, Nantes.
4
Service de Rhumatologie, CHU, Hôpital Sud, Rennes.
5
Service de Rhumatologie, CH du Mans, Le Mans, Service de Médecine Interne, Hopital Cochin, Paris.
6
Service de Médecine Interne, Hopital Cochin, Paris.
7
Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg.
8
Service de Médecine Interne, Hôpital de la Conception, Marseille, Département de Médecine Interne et Maladies Infectieuses, Hôpital Européen, Marseille.
9
Service de Médecine Interne, Claude Huriez Hospital, Université Lille Nord-de-France, Lille.
10
Service de Rhumatologie, CHRU de Rouen, Bois-Guillaume.
11
Service de Rhumatologie, Hôpital Bichat, Paris.
12
Service d'Immuno-Rhumatologie, CHU. Lapeyronie, Montpellier.
13
Service de Rhumatologie, CH J. Monod, Montivilliers.
14
Service de Rhumatologie, Hôpital Gabriel Montpied, Clermont-Ferrand.
15
EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, Brest, Odontologie, CHU Morvan, 29609 Brest, EA 2216, Université Bretagne Occidentale, Brest, France.
16
Department of Oral and Maxillofacial Surgery.
17
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands and.
18
INSERM CIC 0502, CHU Brest, Brest, France.
19
Service de Rhumatologie, CHU de la Cavale Blanche, EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, Brest, alain.saraux@chu-brest.fr.

Abstract

OBJECTIVES:

To determine which outcome measures detected rituximab efficacy in the Tolerance and Efficacy of Rituximab in Sjögren's Disease (TEARS) trial and to create a composite endpoint for future trials in primary SS (pSS).

METHODS:

Post hoc analysis of the multicentre randomized placebo-controlled double-blind TEARS trial. The results were validated using data from two other randomized controlled trials in pSS, assessing rituximab (single-centre trial in the Netherlands) and infliximab, respectively.

RESULTS:

Five outcome measures were improved by rituximab in the TEARS trial: patient-assessed visual analogue scale scores for fatigue, oral dryness and ocular dryness, unstimulated whole salivary flow and ESR. We combined these measures into a composite endpoint, the SS Responder Index (SSRI), and we defined an SSRI-30 response as a ≥30% improvement in at least two of five outcome measures. In TEARS, the proportions of patients with an SSRI-30 response in the rituximab and placebo groups at 6, 16 and 24 weeks were 47% vs 21%, 50% vs 7% and 55% vs 20%, respectively (P < 0.01 for all comparisons). SSRI-30 response rates after 12 and 24 weeks in the single-centre rituximab trial were 68% (13/19) vs 40% (4/10) and 74% (14/19) vs 40% (4/10), respectively. No significant differences in SSRI-30 response rates were found between infliximab and placebo at any of the time points in the infliximab trial.

CONCLUSION:

A core set of outcome measures used in combination suggests that rituximab could be effective and infliximab ineffective in pSS. The SSRI might prove useful as the primary outcome measure for future therapeutic trials in pSS.

KEYWORDS:

efficacy; outcome measures; primary Sjögren’s syndrome; rituximab

PMID:
25957440
DOI:
10.1093/rheumatology/kev114
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center